Logistic advantages of four-section helical CT in the abdomen and pelvis.

BACKGROUND: Multisection helical computed tomography (CT) has the potential for providing data sets with better section profiles, more anatomic coverage, and shorter breath-holding periods. Our purpose was to quantitate these advantages in a clinical setting when imaging the abdomen and pelvis. METHODS: CT parameters including collimation, timing, z-axis coverage, and milliamperes were gathered retrospectively for the image set of both single-section (GE CT/i with 0.8-s rotation) and four-section (GE QX/i Lightspeed with 0.8-s rotation) helical CT scanners. Data were recorded for the abdomen and pelvis CT (n = 30 each), dual-phase liver CT including the pelvis (n = 15 each), and dual-phase pancreas CT (n = 15 each). RESULTS: The abdominal and pelvic CT averaged 128.4 +/- 5.4 s for single-section scanners (70-s delay, two breath-holds of 21.1 and 17. 7 s with a 19.5-s interscan delay) and 92.2 +/- 2.2 s for the four-section scanner (70-s delay and a 22.2-s breath-hold; p < 0. 0001). For the dual liver and pelvis CT, single-section scanners averaged 119.9 +/- 7.5 s (30-s delay, 15.8-s arterial phase, 20.0-s interscan delay, 21.2-s venous phase, 19.5-s interscan delay, and 14. 2 s for the remaining abdomen and pelvis), whereas the four-section scanner averaged 86.8 +/- 2.5 s (30-s delay, 6.7-s arterial phase, 27.9-s interscan delay, and 21.8-s venous phase including the pelvis; p < 0.0001). For the dual pancreas CT, single-section scanners averaged 86.7 +/- 2.5 s (20-s delay, 28.3-s arterial phase, 17.8-s interscan delay, 21.7-s venous phase), whereas the four-section scanner averaged 78.0 +/- 2.9 s (20-s delay, 9.7-s arterial phase, 30.7-s interscan delay, 13.0-s venous phase; p < 0. 0001). CONCLUSION: CT scanners having four-section technology can reduce overall data acquisition times by 10-30% and total milliamperes by 50-60% depending on the protocol with thinner slice profiles.

Hepatic parenchymal enhancement during triple-phase helical CT: can it be used to predict which patients with breast cancer will develop hepatic metastases?

PURPOSE: To evaluate the efficacy of hepatic enhancement characteristics for identification of patients with breast cancer who are at risk for future hepatic metastases. MATERIALS AND METHODS: Triple-phase helical computed tomography (CT) was performed in 60 patients with known breast cancer without visible hepatic metastases. Peak hepatic attenuation and enhancement, and attenuation and enhancement at 25 and 30 seconds were obtained. Ratios of hepatic attenuation or enhancement at 25 and 30 seconds to peak hepatic attenuation or enhancement were calculated. A Wilcoxon rank sum test was used to compare patients with and those without subsequent hepatic metastases. RESULTS: During a mean 18-month follow-up, 18 patients (30%) developed hepatic metastases. Decreases in peak hepatic attenuation and enhancement and increases in hepatic attenuation and enhancement ratios at 25 and 30 seconds were seen in patients who developed metastases compared with those who did not (P < .05). When corrected for chemotherapy interval, these differences were not statistically significant. Using a threshold value of 0.40 or more for the enhancement ratio at 30 seconds resulted in sensitivity of 28%, specificity of 92%, and accuracy of 55%. CONCLUSION: Patients with breast cancer who develop subsequent hepatic metastases have higher relative hepatic arterial perfusion during triple-phase CT; however, after correction for chemotherapy interval, this difference was not statistically significant. Threshold values cannot be used reliably to identify patients who will develop metastases.